Pre-made Sifalimumab benchmark antibody ( Whole mAb, anti-IFNA1 therapeutic antibody, Anti-IFL/IFN3/leIF DD Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-519

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-519 Category Tag

Product Details

Pre-Made Sifalimumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.

Products Name (INN Index)

Pre-Made Sifalimumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody

INN Name

Sifalimumab

Target

IFNA1

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

4ypg:HL:BA

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2009

Companies

Medarex,MedImmune

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Myositis,Psoriasis,Systemic lupus erythematosus

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IFNA1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide